Clinical trial
Safety and Tolerability of Z-100 in Patients With Early HIV Infection
NCT00016692 · Zeria Pharmaceutical, Industry · Terminated
Key facts
| NCT number | NCT00016692 |
|---|---|
| Title | Safety and Tolerability of Z-100 in Patients With Early HIV Infection |
| Official title | A Phase 1b Multicenter Double-Blind, Placebo-Controlled, Randomized Study on the Safety and Tolerability of Z-100 in Early HIV-1 Infected Patients |
| Lead sponsor | Zeria Pharmaceutical, Industry |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | Z-100 |
| First posted | Aug 31, 2001 |
| Last update posted | Apr 27, 2006 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: